Page last updated: 2024-11-08

phenylalanine amide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

phenylalanine amide: inhibits an isoenzyme of alkaline phosphatase; RN given for cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

L-phenylalanine amide : An amino acid amide derived from L-phenylalanine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID445694
CHEMBL ID350320
CHEBI ID21371
SCHEMBL ID244302
MeSH IDM0074199

Synonyms (48)

Synonym
l-phenylalanineamide
BB 0259198
5241-58-7
phenylalanine amide
l-phenylalaninamide
l-phenylalanine amide
phenylalanylamide
DB04029
(s)-2-amino-3-phenylpropanamide
phenylalaninamide
AKOS000301843
(2s)-2-amino-3-phenylpropanamide
chebi:21371 ,
CHEMBL350320 ,
2-amino-3-phenyl-propionamide
bdbm50308386
h-phe-nh2
l-phe-nh2
phenh2
phe-nh2
benzenepropanamide, alpha-amino-, (s)-
unii-pv9t9b2s11
pv9t9b2s11 ,
(2s)-2-amino-3-phenyl-propanamide;l-phenylalaninamide
A829068
(2s)-2-amino-3-phenyl-propanamide
AM20060656
AKOS015854038
benzenepropanamide, .alpha.-amino-, (s)-
benzenepropanamide, .alpha.-amino-, (.alpha.s)-
SCHEMBL244302
M02966
dl-phenylalanine amide
phenylalanine imine
(s)-phenylalaninamide
OBSIQMZKFXFYLV-QMMMGPOBSA-N
Q-102733
DS-1124
CS-W007567
(s)-2-amino-3-phenyl-propionamide
mfcd00038146
(2s)-2-amino-3-phenylpropionyl amide
h-l-phe-nh2
Q27094883
DTXSID601316232
(s)-2-amino-3-phenylpropionyl amide
EN300-209551
Z760046820
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
amino acid amideAn amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group.
phenylalanine derivativeAn amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of phenylalanine by a heteroatom. The definition normally excludes peptides containing phenylalanine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID734192Inhibition of UBR protein in rabbit reticulocyte lysates assessed as inhibition of Tyr-nsP4 substrate degradation at 2 mM by immunoblotting analysis in presence of bestatin2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Development and characterization of monomeric N-end rule inhibitors through in vitro model substrates.
AID52408Displacement of [3H]pentagastrin from Cholecystokinin receptor in mouse cerebral cortex; inactive at 10E-31987Journal of medicinal chemistry, Apr, Volume: 30, Issue:4
Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors.
AID734191Inhibition of UBR protein in rabbit reticulocyte lysates assessed as inhibition of Tyr-nsP4 substrate degradation at 2 mM2013Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6
Development and characterization of monomeric N-end rule inhibitors through in vitro model substrates.
AID462888Displacement of [3H]SP1-7 from NK1 receptor in Sprague-Dawley rat spinal cord membrane2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Discovery of dipeptides with high affinity to the specific binding site for substance P1-7.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (29.17)18.7374
1990's2 (8.33)18.2507
2000's6 (25.00)29.6817
2010's9 (37.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]